Cancer clinical trials in the region Île-de-France
261 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
Rectal cancer
#NCT05723562
Locally Advanced
MSI/dMMR
Systemic Treatment-Naive
MSS
Surgery
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Radiotherapy
Centre Hospitalier Universitaire de Besançon (Besançon), Institut Paoli-Calmettes (Marseille), CHU de Rennes - Hôpital Pontchaillou (Rennes), CHU - Haut-lévêque - Bordeaux (Pessac), Hôpital Saint Antoine AP-HP (Paris)
GlaxoSmithKline
Phase 2
Colon cancer
Rectal cancer
#NCT05706779
Adenocarcinoma
Localized
BRAF
Systemic Treatment-Naive
KRAS G12C
KRAS non G12C
NRAS
Targeted therapy
Hôpital Européen Georges Pompidou - AP-HP (Paris), Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon)
Fédération Francophone de Cancérologie Digestive
Phase 2
Lung cancer
#NCT05688280
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
Immunotherapy
Chemotherapy
Systemic Treatment-Naive
Institut Bergonié (Bordeaux), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Foch (Suresnes)
Immunophotonics
Phase 2
Breast cancer
#NCT05659563
HER2 Negative
HR Positive
Localized
Systemic Treatment-Naive
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Hormone therapy
Hôpital Européen Georges Pompidou - AP-HP (Paris)
MedSIR
Phase 2
Lung cancer
#NCT05609578
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
Systemic Treatment-Naive
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Hôpital Larrey (Toulouse ), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Hôpital Tenon AP-HP (Paris ), CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon ), Centre François Baclesse (Caen ) (and 5 more...)
Mirati Thérapeutique Inc.
Phase 2
Prostate cancer
#NCT05849298
Metastatic Castration-resistant
Immunotherapy
Internal Vectorised Radiotherapy (IVR)
PSMA PET Positive
Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Hôpital Cochin (Paris ), ICANS - Institut de cancérologie Strasbourg Europe (Strasbourg), CHU Caen Normandie (Caen)
Novartis
Phase 2
Lung cancer
#NCT05403385
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Locally Advanced
Metastatic
Immunotherapy
EGFR
ALK
Systemic Treatment-Naive
CHU Caen Normandie (Caen), Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Intercommunal Créteil (Créteil Cedex), Centre Léon Bérard (Lyon), Hôpital de la Timone AP-HM (Marseille) (and 4 more...)
iTeos Belgique SA
Phase 2
Breast cancer
#NCT05297617
HER2 Negative
HR Positive
Localized
Surgery
Hormone therapy
Chemotherapy
Hôpital Privé Drome Ardèche - Clinique Générale - Ramsay Santé (Valence), Centre Hospitalier Universitaire Dupuytren (Limoges), Gustave Roussy (Villejuif), Hôpital Privé Jean Mermoz - Ramsay Santé (Lyon)
UNICANCER
Phase 2
Lymphoma
#NCT05283720
B cell lymphoma
Large B cell lymphoma
Indolent transformed lymphoma
CD20
None
1
2
3 or more
Bispecific T-cell engager antibodies
Hôpital Saint Louis AP-HP (Paris), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Claude Huriez (Lille), Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand), CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy) (and 5 more...)
Abbvie
Phase 2
Colon cancer
Rectal cancer
#NCT05217446
Adenocarcinoma
Metastatic
BRAF
MSI/dMMR
Systemic Treatment-Naive
KRAS G12C
KRAS non G12C
MSS
NRAS
Immunotherapy
Targeted therapy
Immunotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Centre Hospitalier Universitaire de Clermont Ferrand (Clermont-Ferrand), Hôpital Européen Georges Pompidou - AP-HP (Paris), Hôpital Saint Antoine AP-HP (Paris), Institut du cancer de Montpellier (Montpellier)
Pfizer